RNA ▲ +0.2% - Atrium Therapeutics, Inc.
$RNA - Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
27-OCT-2026 06:33 AM ET
Share this post
More filings for $RNA
RNA - Atrium Therapeutics, Inc. - SEC Filing Update (16-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 16, 2026RNA ▼ -5.8% - Atrium Therapeutics, Inc.Nov 12, 2026RNA ▲ +4.7% - Atrium Therapeutics, Inc.Nov 2, 2026RNA ▲ +2.3% - Atrium Therapeutics, Inc.Oct 20, 2026RNA ▲ +2.8% - Atrium Therapeutics, Inc.Sep 21, 2026RNA ▲ +3.7% - Atrium Therapeutics, Inc.Sep 2, 2026
View full $RNA filing history →💬 Comments
Loading comments…
Leave a comment
